表紙
市場調查報告書

結核診斷的全球市場:各診斷試驗的類型,終端用戶,地理的成長率,趨勢及預測(2018年∼2023年)

Tuberculosis Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 659354
出版日期 內容資訊 英文 115 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
結核診斷的全球市場:各診斷試驗的類型,終端用戶,地理的成長率,趨勢及預測(2018年∼2023年) Tuberculosis Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年03月01日內容資訊: 英文 115 Pages
簡介

全球結核診斷市場,預計從2018年開始對2023年的在預測期間內,約4.5%的年複合成長率成長。結核是治癒可能的疾病,不過,在成人中在,尤其是新興經濟國是最常見的死因之一。結核的負擔增加及技術的進步,在對象市場成長裡(上)發揮了重要作用。大規模多樣化的患者人口,結核的盛行率的增加,正在擴大根據民間部門伴隨的醫療基礎設施的增加,亞太地區獲得著最大的市場佔有率。

本報告提供全球結核診斷市場調查,整體市場趨勢,產品、各地區的詳細趨勢,市場成長的影響要素分析,競爭情形,主要企業簡介等,總括性彙整。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 供應商談判力
    • 消費者談判力
    • 新加入廠商的威脅
    • 替代產品及服務的威脅
    • 產業內的競爭
  • 開發平台分析
  • 法律規範

第6章 成長要素,阻礙因素,機會,課題分析(DROC)

  • 市場成長要素
    • 結核與多重抗藥性結核(MDR-TB)的負擔增加
    • R&D投資和集中型產品平台的增加
    • 新興市場上政府的積極推動的增加和意識高漲
  • 市場阻礙因素
    • 結核診斷伴隨的高成本
    • 新興市場上保險的不足或缺乏
  • 市場機會
  • 主要課題

第7章 市場區隔

  • 診斷試驗的各類型
    • 放射線檢驗
    • 實驗室實驗
    • 核酸檢驗
    • 細胞激素檢測實驗
    • 藥物抗性實驗
    • 其他
  • 終端用戶
    • 醫院/診所
    • 診斷/研究實驗室
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • M&A收分析
  • 協定,合作,夥伴關係
  • 新產品的銷售

第9章 主要企業

  • Abbott
  • Becton, Dickinson and Company
  • BioMerieux SA
  • Cepheid
  • F. Hoffmann-La Roche AG
  • Hain Lifescience GmbH
  • Hologic Corporation
  • Qiagen
  • Siemens
  • Thermo Fisher Scientific Inc.

第10章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 61715

Market Overview

The tuberculosis diagnostics market has witnessed a CAGR of 4.56%. Factors propelling the growth of the market include the increasing burden of tuberculosis and multidrug-resistant tuberculosis, increasing R&D investments, intensive product pipelines, and increasing government initiatives in the emerging markets.

The landscape of TB diagnostics has changed dramatically during the past ten years. Moreover, in response to WHO's Global TB Programme, it has implemented a systematic and dynamic process, that is used to evaluate technologies and develop policies, which has, thus, enhanced the growth of the market.

The prevalence rate of tuberculosis is also increasing every year, along with the number of government awareness programs that are influencing people to opt for diagnostic tests (like radiographic tests), which are expected to drive the market during the forecast period.

The market is also expected to witness growth as there is an opportunity for players in the market studied to accelerate the market approval of their pipeline diagnostic products by spurring the fundamental research in TB. Additionally, technological developments in fields, like genomics and proteomics, can be leveraged by diagnostic providers to hasten the process of product development in TB diagnostics.

Scope of the Report

Tuberculosis (TB) is a disease affecting the population across the world. Although tuberculosis is a curable disease, it still remains one of the most common causes of death among adults, particularly in emerging economies. The government initiatives for promoting diagnoses in TB are increasing globally, as governments of various regions are beginning to understand the gap areas in TB management.

Key Market Trends

Nucleic Acid Testing is expected to hold its Highest Market Share among the Diagnostic Tests

In the application type segmentation of the tuberculosis diagnostics market nucleic acid testing is believed to have the largest market size, and is expected to witness a CAGR of 5.4% during the forecast period. This can be attributed to the nucleic acid amplification tests (NAATs) that have been used as diagnostic tools for tuberculosis (TB) in the United States since many years, and which still continue to be used. There are substantial advancements in the diagnosis of TB. Moreover, hese tests have been commercially available in the United States for over two decades that offer better accuracy than other microscopy tests, and even provide greater speed than culture-based tests.

The smear laboratory test is also highly specific in areas with a very high prevalence of tuberculosis. Further, the increasing prevalence rate of TB and advancements in culture-based tests are also expected to drive the market during the forecast period.

Asia-Pacific is the Largest Regional Tuberculosis Diagnostics Market and is expected to be the Same in the Forecast Period

Asia-Pacific is anticipated to exhibit profitable growth over the forecast period due to its high burden as well the rapid proliferation of this disease. The increasing prevalence of TB in Japan helps in the growth of the TB diagnostics market, as the high prevalence of TB creates an urgent demand for effective and quick diagnosis of the disease.

In addition, according to the recent budget announcement, Government of India aims to eliminate tuberculosis (TB) by 2025, which is expected to act as a major factor for the growth of the Asia-Pacific market during the forecast period.

Competitive Landscape

The new product launches, collaborations, mergers and acquisitions, and regional expansions are the key strategic initiatives undertaken by these industry players. The major global players in the tuberculosis diagnostics market are Abbott, Becton, Dickinson and Company, BioMA©rieux SA, Cepheid, and F. Hoffmann-La Roche AG, among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Tuberculosis and Multidrug-resistant Tuberculosis (MDR-TB)
    • 4.2.2 Increasing R&D Investments and Intensive Product Pipelines
    • 4.2.3 Increasing Government Initiatives and Rising Awareness in the Emerging Markets
  • 4.3 Market Restraints
    • 4.3.1 High Costs Associated with Tuberculosis Diagnostics
    • 4.3.2 Low Coverage or Absence of Insurance in the Emerging Markets
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Diagnostic Test Type
    • 5.1.1 Radiographic Test
    • 5.1.2 Laboratory Test
    • 5.1.3 Nucleic Acid Testing
    • 5.1.4 Cytokine Detection Test
    • 5.1.5 Drug Resistance Test
    • 5.1.6 Other Diagnostic Test Types
  • 5.2 By End User
    • 5.2.1 Hospital/Clinics
    • 5.2.2 Diagnostics/Research Laboratory
    • 5.2.3 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Becton, Dickinson and Company
    • 6.1.3 BioMerieux SA
    • 6.1.4 Cepheid
    • 6.1.5 F. Hoffmann-La Roche AG
    • 6.1.6 Hain Lifescience GmbH
    • 6.1.7 Hologic Corporation
    • 6.1.8 Qiagen
    • 6.1.9 AdvaCare Pharma
    • 6.1.10 Thermo Fisher Scientific Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top